Search

Displaying results 3711 - 3720 of 4588 in total
  1. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It is being developed by Alizyme of the UK.

  2. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.

  3. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  4. Drug

    Eflepedocokin alfa

    go.drugbank.com/drugs/DB16366
    Investigational

    [A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666]

  5. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).

  6. Drug

    beta-Alanine

    go.drugbank.com/drugs/DB03107
    Investigational

    beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].

  7. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  8. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    It is being developed by Fibrex Medical Inc.

  9. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.

  10. Drug

    Efavaleukin alfa

    go.drugbank.com/drugs/DB16149
    Investigational

    Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.